Coverage window: May 19-25, 2026
This issue gives a practical cross-section of the field: five-year follow-up after direct neural stem-cell implantation, formal trial records for MSC and exosome programs, and platform papers that refine how cell therapies are made, modeled, and interpreted.
The details to watch are concrete: what was delivered, how it was manufactured, where it went, how patients or models were followed, and what the next study would need to answer.
1. Five-year safety follow-up for NSI-566 in chronic cervical spinal cord injury
Full analysis: A Five-Year Safety Read on Neural Stem Cells in Cervical Spinal Cord Injury
Primary source: https://pubmed.ncbi.nlm.nih.gov/42167221/
A current Stem Cell Reports paper follows three chronic AIS-A cervical spinal cord injury patients for 60 months after implantation of NSI-566, a human spinal cord-derived neural stem cell line. The paper is valuable because it stretches the follow-up window well beyond the immediate surgical period. The full text reports no serious adverse events attributed to the product, surgery, or immunosuppression, while functional and neurophysiological observations remain descriptive.
Why it matters: for CNS cell therapy, delivery is part of the product profile. A directly injected neural cell product has to be judged together with surgery, immunosuppression, imaging follow-up, and long-term monitoring.
2. Intranasal MSC-exosome trial in mild-to-moderate Alzheimer's disease
Full analysis: Reading the CB-Exo-A600 Alzheimer's Exosome Trial Before Results Exist
Primary source: https://clinicaltrials.gov/study/NCT07457125
ClinicalTrials.gov lists CB-Exo-A600 as a recruiting Phase 1/2 study of intranasal umbilical-cord MSC-derived exosomes in mild-to-moderate Alzheimer's disease. The design includes a dose-escalation phase and a randomized, double-blind, placebo-controlled expansion component, with serious adverse events as the primary outcome.
Why it matters: the public record is detailed enough to follow over time: product source, route, dose escalation, masking, placebo control, and safety as the first question. That gives future results a clear frame.
3. Allogeneic MSCs enter a six-patient Phase 1 NMOSD relapse study
Primary source: https://clinicaltrials.gov/study/NCT07595965
Corestemchemon posted a not-yet-recruiting Phase 1 study of CE211NS21, described in the registry as allogeneic bone marrow-derived mesenchymal stem cells, for severe AQP4-IgG-positive neuromyelitis optica spectrum disorder relapse. Enrollment is six, and the primary measures are dose-limiting toxicity and adverse events.
Why it matters: NMOSD sits outside classic replacement therapy, but it is a serious neurologic disease where immune modulation matters. This record shows another place where MSC products are being moved into a formal clinical design.
4. Adult RPE progenitor replacement package for dry AMD reaches the IND-enabling stage
Primary source: https://pubmed.ncbi.nlm.nih.gov/42055007/
A Cell Reports Medicine paper describes GMP process work and GLP-style preclinical studies supporting an IND application for RPESC-RPE-4W, an adult RPE progenitor-cell product for dry age-related macular degeneration.
Why it matters: retina is one of the clearest proving grounds for replacement cell products. The paper is notable for the package around the product: GMP process work, reproducibility, safety studies, and disease-model rationale before human testing begins.
5. A human iPSC corticospinal tract-on-a-chip
Primary source: https://pubmed.ncbi.nlm.nih.gov/42161268/
A Cell Reports Methods paper reports a human iPSC-based microfluidic platform modeling corticospinal neuron to spinal motor neuron connectivity, including regionally specific astrocyte subtypes and multielectrode-array readouts.
Why it matters: corticospinal degeneration is hard to study in human-relevant systems. A circuit-level model with defined neuron and astrocyte compartments can help researchers ask sharper questions about degeneration, connectivity, and screening.
6. An ALS iPSC motor-neuron model narrows a perineuronal-net question
Primary source: https://pubmed.ncbi.nlm.nih.gov/42156505/
A Communications Biology paper reports that ALS-associated mutations did not alter perineuronal-net-like structure formation in the tested human pluripotent stem-cell-derived motor-neuron system.
Why it matters: model papers are useful when they show what changes and when they show what does not. This one helps keep the perineuronal-net question in proportion for ALS iPSC motor-neuron systems.
7. A precision-product argument for MSC therapy
Primary source: https://pubmed.ncbi.nlm.nih.gov/42167216/
A Cell Stem Cell perspective argues that MSC therapy development needs a more context-dependent product framework, including a sharper view of potency, cryopreservation, apoptosis, metabolic activity, paracrine signaling, and host efferocytosis.
Why it matters: MSC products are often discussed as if they belong to one interchangeable category. The better question is more specific: which product, in which disease context, with which potency logic, and under which handling conditions.